Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Review and Restructing

4 Dec 2006 16:08

Torex Retail PLC04 December 2006 TOREX RETAIL PLC ANNOUNCES PHASE TWO OF CORPORATE RESTRUCTURING TO INCREASE FOCUS ON CORE BUSINESSES THROUGH DISPOSAL OF NON CORE OPERATIONS AND DIRECTORSHIP CHANGES Torex Retail Plc ("Torex"), the leading international supplier of innovativecomputer systems to the retail sector, is pleased to announce the sale of noncore operations. A package of businesses, product lines, assets and distribution rightscomprising Leisure, Hotel and Digital Signage systems activities has been soldfor a maximum consideration of £8.0 million. The package of Non Core Operations have been sold to Shoo 291 Limited, a newcompany formed to effect the acquisitions by Ed Dayan and Mark Pearman who areboth Directors of Torex, but who will be stepping down from the Board withimmediate effect. These Non Core Operations are expected to achieve full yearrevenues of an estimated £6.5 million in 2006 and comprise a number of smallcompanies and businesses employing 65 people across the UK, US, South Africa ,Australia and Malaysia. Separately, Ace Casino Equipment Pty Limited, a South African subsidiaryoperating in the casino and gaming sector has been sold to Source IP Limited fora consideration of £1.8m. The combined effect of the divestments on full year revenues and operatingprofit is estimated at a reduction of £1.8m and £0.3m respectively. Thesebusiness units have a disproportionately high level of activity in the lastquarter of the year. The disposal increases the focus of the Group on its main markets in Retail,Hospitality, Quick Service Restaurants and Petroleum & Convenience freeing upvaluable management time and resources. Chris Moore, Chairman of Torex, commented: "The disposal of these small non core operations significantly sharpens thefocus of the Group both in terms of sector and geographic concentration. Due totheir small size and contribution the non core operations have not, and willnot, achieve their true potential in a large group like Torex. It is thereforeright for them to move forward under new ownership which will give them thefocus and investment they require. On behalf of the Board I would like to thank all the Torex employees who aretransferring to the new company for their hard work and dedication during theiremployment with our Group. The Board would like to thank Ed Dayan and Mark Pearman for their contributionto the development of the Group and we wish them and their new team everysuccess in their new venture." BOARD CHANGES In addition Torex confirms that arrangements have been made for restructuring ofthe Board. Chris Moore will remain on the Board as Non Executive Chairman untilsuch time as the company appoints a new independent Non Executive Chairman. Mr Moore has entered into a full time consultancy agreement with Torex for aminimum period of 12 months under which he will actively manage top level clientrelationships in certain major global accounts. A fixed term consultancy arrangement has also been agreed with Nigel Horn, LegalDirector and Company Secretary, who will leave the Board with immediate effect. Marcus Leek, Chief Finance Officer has been appointed Company Secretary pendinga permanent appointment. Chris Moore in his position as Non Executive Chairman and the Directors nowleaving Torex continue to hold substantial shareholdings and support thebusiness going forward. Neil Mitchell, Chief Executive Officer of Torex stated:- "Since my arrival as Chief Executive Officer of Torex Retail plc and as part ofmy strategic review, this re-focusing of the Group around core operations andDirectorship changes to streamline the Board are significant steps in enabling afresh perspective being brought by new management in aggressively growing thenew Torex Retail going forward. Trading remains in line with market guidanceand we expect to post further positive updates including information on newcontract wins in the near future." Enquiries:- R Neil W Mitchell Chief Executive OfficerMarcus Leek Chief Finance OfficerGavin Palmer Corporate Governance & Investor Relations ManagerTorex Retail Plc0870 300 6061 Ginny Pullbrook/Sebastian Hoyle/Freida Moore/Lucie HollowayCitigate Dewe Rogerson020 7638 9571 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jan 20267:00 amRNSSecondary Trading Following Cancellation
7th Jan 20267:00 amRNSCancellation - Tissue Regenix Group Plc
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
17th Dec 20256:00 pmRNSTissue Regenix Group
8th Dec 20257:00 amRNSUpdate re. proposed cancellation of shares
4th Dec 20252:40 pmRNSProposed £17.5m CLN raise, cancellation of Trading
1st Dec 20257:00 amRNSFurther re. financial update and funding plans
7th Nov 20257:00 amRNSFinancial update and funding plans
22nd Oct 20253:29 pmRNSStatement re. Suspension
22nd Oct 20252:02 pmRNSSuspension - Tissue Regenix Group PLC
17th Oct 20257:00 amRNSCFO joins Board
16th Oct 20257:00 amRNSUpdate re. FY24 & H125 restatement & Board Changes
9th Oct 20257:00 amRNSHolding(s) in Company
6th Oct 20253:29 pmRNSHolding(s) in Company
3rd Oct 20253:01 pmRNSHolding(s) in Company
2nd Oct 20254:43 pmRNSHolding(s) in Company
1st Oct 20255:35 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
17th Sep 20257:00 amRNSNotice of Results
8th Sep 20257:01 amRNSHalf-Year Trading Update and Notice of Results
8th Sep 20257:00 amRNSBoard Changes
1st Aug 20257:00 amRNSDirectorate Change
23rd Jul 20251:52 pmRNSResult of AGM
4th Jul 20257:00 amRNSGrant of share options
27th Jun 20257:00 amRNSPosting of Annual Report & Notice of AGM
25th Jun 20257:00 amRNSFinal results for the year ended 31 December 2024
9th Jun 20257:00 amRNSCE & UKCA certification for OrthoPure® XT
24th Apr 20259:38 amRNSForm 8.5 (EPT/NON-RI)- Tissue Regenix Group Plc
15th Apr 20259:23 amRNSForm 8.5 (EPT/NON-RI)
10th Apr 20259:09 amRNSForm 8.5 (EPT/NON-RI)
9th Apr 202510:45 amRNSForm 8.5 (EPT/NON-RI)
8th Apr 20257:00 amRNSConclusion of Strategic Review & Offer Period
7th Apr 20258:46 amRNSForm 8.5 (EPT/NON-RI)
1st Apr 20259:12 amRNSForm 8.5 (EPT/NON-RI)
31st Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
27th Mar 20257:00 amRNSEuropean patent granted
25th Mar 20258:58 amRNSForm 8.5- Tissue Regenix Group Plc
21st Mar 20258:36 amRNSForm 8.5 (EPT/NON-RI)
20th Mar 20259:19 amRNSForm 8.5 (EPT/NON-RI)
19th Mar 20258:55 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20257:00 amRNSCompany update
12th Mar 20259:27 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 20259:30 amRNSForm 8.5 (EPT/NON-RI)
6th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
5th Mar 20258:54 amRNSForm 8.5 (EPT/NON-RI)
4th Mar 20259:28 amRNSForm 8.5 (EPT/NON-RI)
3rd Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 20258:56 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.